Federated Hermes Inc. Has $7.91 Million Stock Position in GSK plc (NYSE:GSK)

Federated Hermes Inc. reduced its stake in shares of GSK plc (NYSE:GSK) by 2.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 213,448 shares of the pharmaceutical company’s stock after selling 5,939 shares during the quarter. Federated Hermes Inc.’s holdings in GSK were worth $7,910,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of GSK. IFP Advisors Inc grew its holdings in shares of GSK by 22.9% during the 3rd quarter. IFP Advisors Inc now owns 7,035 shares of the pharmaceutical company’s stock worth $255,000 after purchasing an additional 1,312 shares in the last quarter. Washington Trust Advisors Inc. bought a new stake in shares of GSK during the 3rd quarter worth $53,000. UMB Bank n.a. lifted its position in shares of GSK by 4.8% during the 3rd quarter. UMB Bank n.a. now owns 6,462 shares of the pharmaceutical company’s stock worth $234,000 after buying an additional 297 shares during the last quarter. Kempner Capital Management Inc. bought a new stake in shares of GSK during the 3rd quarter worth $2,735,000. Finally, Aaron Wealth Advisors LLC lifted its position in shares of GSK by 5.6% during the 3rd quarter. Aaron Wealth Advisors LLC now owns 12,098 shares of the pharmaceutical company’s stock worth $439,000 after buying an additional 637 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Price Performance

Shares of GSK opened at $40.88 on Thursday. GSK plc has a 1 year low of $33.33 and a 1 year high of $43.84. The company has a debt-to-equity ratio of 1.19, a current ratio of 0.88 and a quick ratio of 0.62. The company has a market capitalization of $84.72 billion, a price-to-earnings ratio of 13.58, a price-to-earnings-growth ratio of 1.43 and a beta of 0.64. The business has a 50-day moving average of $41.86 and a 200-day moving average of $38.91.

GSK (NYSE:GSK) last released its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.04). GSK had a return on equity of 51.45% and a net margin of 16.24%. The business had revenue of $10 billion for the quarter, compared to analyst estimates of $9.79 billion. As a group, equities research analysts anticipate that GSK plc will post 4.03 earnings per share for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, April 11th. Shareholders of record on Friday, February 23rd were paid a $0.3564 dividend. This represents a $1.43 dividend on an annualized basis and a yield of 3.49%. The ex-dividend date was Thursday, February 22nd. This is a boost from GSK’s previous quarterly dividend of $0.34. GSK’s dividend payout ratio (DPR) is 52.82%.

Wall Street Analysts Forecast Growth

GSK has been the subject of several recent analyst reports. Jefferies Financial Group upgraded GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Guggenheim upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Finally, Morgan Stanley began coverage on GSK in a research report on Tuesday, January 23rd. They issued an “equal weight” rating for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.